Premium
Daratumumab is effective in the relapsed or refractory systemic light‐chain amyloidosis but associated with high infection burden in a frail real‐life population
Author(s) -
Van de Wyngaert Zoe,
Carpentier Benjamin,
Pascal Laurent,
LionneHuyghe Pauline,
Leduc Isabelle,
Srour Micha,
Vasseur Michele,
Demarquette Helene,
Terriou Louis,
Herbaux Charles,
Manier Salomon,
Bossard JeanBaptiste,
Barbieux Sarah,
Chauvet Paul,
Willaume Alexandre,
Nudel Morgane,
Bories Claire,
Gibier JeanBaptiste,
Facon Thierry,
Boyle Eileen M.
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16282
Subject(s) - daratumumab , al amyloidosis , medicine , refractory (planetary science) , amyloidosis , population , oncology , multiple myeloma , aa amyloidosis , intensive care medicine , immunoglobulin light chain , immunology , lenalidomide , antibody , disease , biology , environmental health , astrobiology , familial mediterranean fever